Please login to the form below

Not currently logged in
Email:
Password:

Sivextro

This page shows the latest Sivextro news and features for those working in and with pharma, biotech and healthcare.

Merck defeated in antibiotic patent case in US

Merck defeated in antibiotic patent case in US

In addition to Cubicin, buying Cubist has also given Merck Sivextro (tedizolid phosphate) - anther treatment for skin and skin structure infections, and Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal and urinary

Latest news

  • Merck prepares filings for Clostridium antibody Merck prepares filings for Clostridium antibody

    Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa

  • Actavis gets FDA nod for new antibiotic Actavis gets FDA nod for new antibiotic

    Avycaz' closest rival among these is Cubist Pharmaceuticals' Zerbaxa (ceftolozane/tazobactam) - which has been tipped as a $1bn-plus product - while the others are Cubist's Sivextro (tedizolid), Durata/Actavis' Dalvance

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Antibiotics among 7 new drugs backed by EMA. The Medicines Company’ s Orbactiv and Cubist’ s Sivextro set for European approval. ... Orbactiv and Sivextro are already recommended by the US FDA to treat these forms of infections.

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    The approval of Zerbaxa adds to Cubist's stable of antibiotics, which include $1bn-a-year blockbuster Cubicin (daptomycin) as well as recently-approved Sivextro (tedizolid phosphate) for acute bacterial skin ... In addition to Sivextro, the agency also

  • UPDATE: Merck to acquire Cubist for $8.4bn UPDATE: Merck to acquire Cubist for $8.4bn

    Cubicin is Cubist's leading product. The company's portfolio has been strengthened recently by the approval of Sivextro (tedizolid phosphate) to treat acute bacterial skin and skin structure infections, while

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    For Cubist its beliefs have been justified with the approval of the new antibiotic Sivextro (tedizolid phosphate) to treat acute bacterial skin and skin structure infections, while another drug - ceftolozane/tazobactam - ... Cubist's pipeline. Phase I.

  • Pharma deals during December 2014 Pharma deals during December 2014

    Approved in 2014, tedizolid phosphate ( Sivextro) is for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including MRSA.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics